JAG 201
Alternative Names: JAG-201Latest Information Update: 28 Mar 2025
At a glance
- Originator Broad Institute
- Developer Jaguar Gene Therapy
- Class Behavioural disorder therapies; Gene therapies
- Mechanism of Action Gene transference; SHANK3 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Telomeric 22q13 Monosomy Syndrome
- No development reported Autistic disorder
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Autistic-disorder in USA (Intraventricular, Injection)
- 28 Oct 2024 Jaguar Gene Therapy plans a phase I/II trial for Telomeric-22q13-Monosomy-Syndrome (In Children) in USA (Intraventricular) (NCT06662188)
- 12 Jul 2024 JAG 201 receives Fast Track designation for Autistic disorder [Intraventricular,Injection] in USA before July 2024